HyperRAB S/D and the rabies vaccine should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRAB S/D should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. HyperRAB S/D is preservative and latex-free and comes in 2 mL and 10 mL vial sizes.
For more information about HyperRAB S/D, login to biosupply.fffenterprises.com
HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant. HyperRHO S/D Full Dose may be used to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood cells. HyperRHO S/D Full Dose comes in a 300 ugm single-dose syringe and a 1 mL syringe (10 pack).
HyperRHO S/D Mini-Dose is recommended to prevent the isoimmunization of Rho(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation. HyperRHO S/D Mini-Dose is available in a 50 ugm single-dose syringe (10 pack).
For more information about HyperRHO S/D, login to biosupply.fffenterprises.com